TCGA-AR-A0TW-01A-11R-A084-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 100
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.490
- MTORC1_SIGNALING+0.460
- PROTEIN_SECRETION+0.410
- OXIDATIVE_PHOSPHORYLATION+0.380
- INTERFERON_GAMMA_RESPONSE+0.370
- INTERFERON_ALPHA_RESPONSE+0.360
- MYC_TARGETS_V1+0.350
- PEROXISOME+0.350
- ADIPOGENESIS+0.340
- ALLOGRAFT_REJECTION+0.330
Top 10 suppressed
- NOTCH_SIGNALING-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- HEDGEHOG_SIGNALING-0.360
- WNT_BETA_CATENIN_SIGNALING-0.340
- MYOGENESIS-0.320
- UV_RESPONSE_DN-0.260
- ANGIOGENESIS-0.240
- KRAS_SIGNALING_DN-0.240
- COAGULATION-0.220
- APICAL_JUNCTION-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG510 | — | — | 0.842 |
| 2 | BS_W80TJC27 | EPN | Supratentorial EPN | 0.829 |
| 3 | c7aea5a2-5772-4475-8ca6-326193eeb69e | — | — | 0.815 |
| 4 | 4769f22f-eeaf-4108-9555-55cc5d6ae27b | — | — | 0.813 |
| 5 | s0122170 | — | — | 0.809 |
| 6 | SRR6013495 | — | cohortA1 | 0.807 |
| 7 | bf312cd5-e251-4d63-95b5-c379b3ef5ded | — | — | 0.804 |
| 8 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.803 |
| 9 | R149 | — | — | 0.797 |
| 10 | c340b651-bd01-4194-a67b-e801d0feeb2b | — | — | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.460 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| PEROXISOME | 0.350 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.340 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |